Intercure (INCR) vs Talphera (TLPH)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Talphera (TLPH) has outperformed Intercure (INCR) over the past year, losing 18.2% versus a loss of 37.5%. Over five years, INCR leads with a -85.8% price change compared with -94.7% for TLPH. Intercure is the larger company by market cap ($77.6 million vs $56.1 million), about 1.4 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | INCR | TLPH |
|---|---|---|
| Share price | $5.17 | $1.08 |
| Market cap | $77.57M | $56.06M |
| 1-day change | +2.99% | 0.00% |
| YTD return | +10.55% | -5.26% |
| 1-year return | -37.52% | -18.18% |
| 5-year return | -85.81% | -94.71% |
| EPS (TTM) | $-0.95 | $-0.26 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $8.40 | $1.57 |
| 52-week low | $3.40 | $0.69 |
| Distance from 52-week high | -38.45% | -31.21% |
| Analyst consensus | — | none |
| Avg. price target upside | — | +189.81% |
| Average volume | 21.73K | 238.38K |
| Shares outstanding | 15.00M | 51.91M |
| Employees | 285 | 12 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- TLPH has outperformed INCR by 19.3 percentage points over the past year.
About Intercure
INCR stock →InterCure Ltd., together with its subsidiaries, engages in the production, manufacturing, and distribution of pharmaceutical-grade cannabis and cannabis-based products for medical use in Israel and internationally. The company offers dried cannabis inflorescences and cannabis extract mixed with oil.
Health Care · Biotechnology: Pharmaceutical Preparations · 285 employees
About Talphera
TLPH stock →Talphera, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of therapies for use in medically supervised settings. The company's lead product candidate, Niyad, is a lyophilized formulation of nafamostat that acts as a regional anticoagulant for infusion into the extracorporeal circuit.
Health Care · Biotechnology: Pharmaceutical Preparations · 12 employees
INCR vs TLPH FAQ
Which is bigger, Intercure or Talphera?
Intercure (INCR) is larger, with a market capitalization of $77.57M compared with $56.06M for Talphera (TLPH).
Which stock has performed better over the past year, INCR or TLPH?
TLPH returned -18.18% over the past 12 months, compared with -37.52% for INCR (price return, excluding dividends). Past performance does not predict future results.
Are Intercure and Talphera in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.